Persistent Epstein-Barr Antibodies May Support MS Diagnosis

Why It Matters

The finding offers clinicians a low‑cost, laboratory‑based tool to improve diagnostic confidence for MS, potentially accelerating treatment decisions and reducing misdiagnosis.

Key Takeaways

• 96% of MS patients showed persistently high EBV antibodies
• Other neuroinflammatory diseases rarely exhibited sustained EBV antibody elevation
• Longitudinal EBV antibody testing improves diagnostic confidence in ambiguous cases
• Biomarker complements MRI and clinical criteria, not a standalone test

Pulse Analysis

The relationship between Epstein‑Barr virus (EBV) and multiple sclerosis (MS) has long intrigued neurologists. While virtually all adults carry EBV, epidemiological studies have repeatedly shown that a prior EBV infection raises the risk of developing MS by several folds. Recent advances in serology have enabled precise quantification of antibodies against EBV nuclear antigen‑1 (EBNA‑1), a protein that persists after infection. Understanding whether these immune signatures differ between MS and other neuroinflammatory disorders could provide a much‑needed laboratory clue in a field dominated by imaging and clinical assessment.

The JAMA Neurology study examined roughly 2,000 patients with various neurological diseases alongside a matched healthy cohort, focusing on EBNA‑1 antibody levels. Remarkably, 96 % of individuals diagnosed with MS maintained high EBV antibody titers across multiple blood draws, whereas only a minority of patients with conditions such as neuromyelitis optica or acute demyelinating encephalomyelitis displayed similar persistence. This longitudinal pattern distinguished MS with a specificity that single‑time‑point testing could not achieve, suggesting that repeated serologic monitoring may serve as a practical adjunctive biomarker.

For clinicians, incorporating serial EBV antibody measurements could shorten the diagnostic odyssey for patients whose MRI findings are equivocal or who present with atypical symptoms. The test is inexpensive, widely available, and can be ordered alongside routine labs, offering an objective data point that complements the McDonald criteria. Nonetheless, experts caution against overreliance; antibody status alone cannot confirm MS and must be interpreted within the broader clinical context. Ongoing trials are now evaluating whether early identification of high‑titer EBV carriers can guide preventive strategies or targeted antiviral therapies.